Replay - Reviewing Drug Pricing Options: From AWP to AAC and Regulatory Impacts

Capital Rx

Capital Rx

On August 23, 2022, Capital Rx President Matt Gibbs led an AHIP Webinar focused on drug pricing indexes, the strengths and weaknesses of the various benchmarks, the Consolidated Appropriations Act (CAA), and pointers for how to recognize and fix structural issues with most pharmacy benefit program contracts.

The price of a drug shouldn’t “disappear” when it leaves the pharmacy, but it does! Average Wholesale Price (AWP) still drives 99% of the market, despite options like NADAC being available, and MAC lists are still a thing. While there are several problems with drug prices, NADAC has been a deflationary index, and there are signs of brand deflation for the first time in years. The system allows ambiguity to be common practice, and we no longer need to accept it! Check out the replay for detail on these topics and much more.

Reach out if you have questions or want to learn more about Capital Rx’s pharmacy benefits solutions and next-generation enterprise pharmacy platform, JUDI™.